Ranere, Stephen W.

Stephen W. Ranere

Partner

stephen.ranere@lw.com
    Ranere, Stephen W.

    Stephen W. Ranere

    Partner

    stephen.ranere@lw.com
    "Routinely called upon to advise emerging companies and venture capital firms on technology deals."

    Chambers USA 2024

    "A great lawyer who takes a highly practical approach."

    Chambers USA 2024

    "Stephen is great. He is very experienced, very commercial and super responsive."

    Chambers USA 2024

    "Strikes a wonderful balance between understanding every issue that can confront a venture-backed start-up company on the one hand and how to practically address those issues on the other hand."

    The Legal 500 US 2024

    "He is very practical and has a wealth of knowledge. He is also incredibly responsive."

    Chambers USA 2023

    "Stephen Ranere focuses on the desired business outcome, which is most important to clients."

    Chambers USA 2023

    "Stephen handles sophisticated transactions well, he's strong in the space."

    Chambers USA 2023

    "Stephen Ranere is fantastic."

    Chambers USA 2022

    "Phenomenal." "Great to work with and a very effective negotiator."

    Chambers USA 2020

    Profile

    Stephen Ranere is a partner in Latham’s Boston office and a member of the firm’s Emerging Companies & Growth Practice. He represents technology and life sciences companies from startup through IPO and beyond.

    Stephen advises companies in the areas of:

    • Mergers and acquisitions
    • Early-stage formation and strategy
    • Venture capital and growth equity financings
    • Public offerings of securities
    • Public company representation
    • Corporate governance matters

    Experience

    Stephen's recent representative transactions include advising:

    Life Sciences and Digital Health

    • Affini-T Therapeutics on its US$175 million equity financing
    • Overjet on its US$53 million Series C financing and numerous other debt and equity financings
    • PathAI on its US$165 million Series C financing
    • BlueWhale Bio on its US$18 million seed financing 
    • Rapid Micro Biosystems on its IPO and multiple private financings and strategic transactions
    • Neurogene on its US$115 million equity financing and numerous other private financings
    • Kiniksa Pharmaceuticals on its US$150 million IPO and multiple private financings and strategic transactions
    • CloudHealth on its sale to VMware, Inc.
    • Owkin on its US$180 million investment from Sanofi, US$80 million investment from BMS, and other equity financings

    Technology

    • MadHive on its US$300 million investment from Goldman Sachs Asset Management
    • Merlin Labs on its US$105 million Series B financing
    • OfferFit on its numerous debt and equity financings 
    • Robin on its US$30 million Series C financing
    • Riversand Technologies on its sale to Syndigo
    • Evolv Technology on its US$1.7 billion SPAC merger with NewHold Investment Corporation
    • Actifio on its sale to Google and numerous debt and equity financings
    • Charles River Systems on its US$2.6 billion sale to State Street Corporation
    • Amphenol on its US$400 million acquisition of SSI Controls Technologies
    • Veracode on its US$614 million sale to CA Technologies
    • Care.com in its IPO and numerous acquisitions
    • Zipcar on its IPO and sale to Avis Budget Group

    Qualifications

    Bar Qualification

    • Massachusetts

    Education

    • JD, Suffolk University Law School, 2008
      summa cum laude
    • BA, Harvard University, 2000

    Practices

    Industries

    Recognition

    News & Insights

    Read More